Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002048
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic CDC Group II or Have Persistent Generalized Lymphadenopathy CDC Group III
Sponsor:
Glaxo Wellcome
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic CDC Group II or Have Persistent Generalized Lymphadenopathy CDC Group III
Status:
COMPLETED
Status Verified Date:
1989-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and tolerance of chronic administration of Retrovir AZT in HIV-infected adult patients without clinical manifestations of disease To assess the efficacy of AZT therapy in the treatment of HIV disease in these patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 21 | None | None | None |